Table 1 Baseline clinical characteristics
Variable | Total (n = 426) | Non-SCAC (n = 320) | SCAC (n = 106) | P value |
|---|---|---|---|---|
Age, years | 67.14 ± 10.29 | 65.62 ± 10.11 | 71.74 ± 9.44 |  < 0.001 |
Male sex, % | 281 (66.0) | 213 (66.6) | 68 (64.2) | 0.650 |
BMI, kg/m2 | 24.40 ± 2.84 | 24.44 ± 2.80 | 24.29 ± 2.98 | 0.653 |
Smoking, % | 221 (51.9) | 170 (53.1) | 51 (48.1) | 0.371 |
Family history, % | 103 (24.2) | 75 (23.4) | 28 (26.4) | 0.535 |
Hypertension, % | 303 (71.1) | 221 (69.1) | 82 (77.4) | 0.102 |
Diabetes, % | 124 (29.1) | 84 (26.2) | 40 (37.7) | 0.024 |
Prior MI, % | 42 (9.9) | 30 (9.4) | 12 (11.3) | 0.560 |
Prior PCI % | 90 (21.1) | 62 (19.4) | 28 (26.4) | 0.124 |
Clinical presentation | Â | Â | Â | 0.980 |
SCAD | 354 (83.1) | 266 (83.1) | 88 (83.0) | Â |
ACS | 72 (16.9) | 54 (16.9) | 18 (17.0) | Â |
eGFR, ml/min/1.73m2 | 80.89 ± 20.79 | 82.51 ± 20.64 | 76.00 ± 20.56 | 0.005 |
HbA1c, % | 6.34 ± 1.38 | 6.26 ± 1.33 | 6.59 ± 1.48 | 0.031 |
TG, mmol/L | 1.63 ± 0.89 | 1.66 ± 0.87 | 1.54 ± 0.94 | 0.204 |
TC, mmol/L | 4.17 ± 1.01 | 4.14 ± 0.97 | 4.24 ± 1.14 | 0.381 |
HDL, mmol /L | 1.06 ± 0.26 | 1.05 ± 0.26 | 1.07 ± 0.28 | 0.465 |
LDL, mmol/L | 2.66 ± 0.85 | 2.63 ± 0.82 | 2.74 ± 0.94 | 0.230 |
Serum FFAs, mmol/dl | 5.51 ± 1.96 | 5.13 ± 1.73 | 6.62 ± 2.17 |  < 0.001 |
SBP, mmHg | 131.50 ± 17.02 | 130.03 ± 16.03 | 135.93 ± 19.10 | 0.002 |
DBP, mmHg | 75.01 ± 10.52 | 75.48 ± 10.38 | 73.62 ± 10.89 | 0.116 |
PP, mmHg | 56.51 ± 13.63 | 54.55 ± 12.55 | 62.41 ± 15.07 |  < 0.001 |
Prior medical treatment | Â | Â | Â | Â |
Anti-platelet drugs (n/%) | 119 (28.0) | 84 (26.3) | 35 (33.0) | 0.184 |
Statins (n/%) | 99 (23.2) | 73 (22.8) | 26 (24.5) | 0.717 |
ACEI/ARB (n/%) | 194 (45.5) | 139 (43.4) | 55 (51.9) | 0.130 |
β-blockers (n/%) | 81 (19.0) | 55 (17.2) | 26 (24.5) | 0.095 |
CCB (n/%) | 144 (33.8) | 102 (31.9) | 42 (39.6) | 0.144 |
Insulin (n/%) | 32 (7.5) | 21 (6.6) | 11 (10.4) | 0.197 |